BCM
ACRS icon

BML Capital Management’s Aclaris Therapeutics ACRS Stock Holding History

BML Capital Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$53.4M Hold
14,250,000
– – 34.31% 1
2025
Q4 		$42.9M Hold
14,250,000
– – 37.08% 1
2025
Q3 		$27.1M Hold
14,250,000
– – 24.79% 1
2025
Q2 		$20.2M Hold
14,250,000
– – 15.31% 3
2025
Q1 		$21.8M Hold
14,250,000
– – 17.65% 2
2024
Q4 		$35.3M Hold
14,250,000
– – 21.95% 1
2024
Q3 		$16.4M Buy
14,250,000
+1,261,866
+10% +$1.55M 9.64% 4
2024
Q2 		$14.3M Buy
12,988,134
+3,592,200
+38% +$4.22M 10.2% 4
2024
Q1 		$11.7M Buy
9,395,934
+8,742,827
+1,339% +$10.4M 7.68% 5
2023
Q4 		$686K Buy
+653,107
New +$1.99M 0.52% 28

Other funds holding ACRS

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

BML Capital Management's ACRS Position: Q1 2026 in Review

BML Capital Management held its Aclaris Therapeutics (ACRS) position steady in Q1 2026 at 14,250,000 shares worth $53.4M. The position accounts for 34.31% of the portfolio, ranked #1.

BML Capital Management first reported a position in ACRS in Q4 2023 and has held it in 10 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • BML Capital Management held 14,250,000 shares of Aclaris Therapeutics worth $53.4M as of Q1 2026.
  • BML Capital Management left its Aclaris Therapeutics share count unchanged in Q1 2026.
  • Aclaris Therapeutics made up 34.31% of BML Capital Management's portfolio in Q1 2026, its #1 holding.
  • BML Capital Management first reported a position in Aclaris Therapeutics in Q4 2023 and has held it in 10 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on BML Capital Management's 13F filing for Q1 2026, filed 6 May 2026.